Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6330357 | 0.85 | KDR (0.65) | KDRGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6330228 | 0.85 | KDR (0.65) | KDRGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6288100 | 0.82 | SMN1; SMN2 (0.59) | KDRSMN1; SMN2MEN1NPC1MAPT | |
| SCHEMBL4601325 | 0.79 | ALDH1A1 (0.61) | KDRGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6336629 | 0.78 | KDR (0.69) | KDRGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6328597 | 0.78 | KDR (0.64) | KDRALDH1A1SMN1; SMN2MEN1NPC1 | |
| SCHEMBL6332010 | 0.77 | KDR (0.72) | KDRGAAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6330936 | 0.77 | KDR (0.62) | KDRSMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL30917222 | 0.76 | MAPT (0.70) | GAAALDH1A1SMN1; SMN2MEN1NPC1 | |
| SCHEMBL16342961 | 0.76 | MAPT (0.70) | GAAALDH1A1SMN1; SMN2MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | claimed |
| US-20050228031-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228031-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885GAA 1166/4885ALDH1A1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.